Submitted:
07 April 2024
Posted:
08 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Experimental Animals
4.2. Experimental Design
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Piché, M.-E.; Tchernof, A.; Després, J.-P. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ. Res. 2020, 126 (11), 1477–1500. [CrossRef]
- Babenko, A. Yu.; Golikova, T. I. Obesity as a predictor of metabolic disorders and a target for personalized interventions. Rossiiskiy zhurnal personalizirovannoy meditsiny 2021, 1 (1), 59–94.
- Chai, Z.; Yan, Y.; Zan, S.; Meng, X.; Zhang, F. Probiotic-fermented blueberry pomace alleviates obesity and hyperlipidemia in high-fat diet C57BL/6J mice. Food Res. Int. 2022, 157, 111396. [CrossRef]
- Perdomo, C. M.; Cohen, R. V; Sumithran, P.; Clément, K.; Frühbeck, G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet 2023, 401 (10382), 1116–1130. [CrossRef]
- Karr, S. Epidemiology and management of hyperlipidemia. Am. J. Manag. Care 2017, 23 (9 Suppl), S139–S148.
- Santos-Baez, L. S.; Ginsberg, H. N. Hypertriglyceridemia—Causes, Significance, and Approaches to Therapy. Front. Endocrinol. (Lausanne). 2020, 11. [CrossRef]
- Gao, M.; Jebb, S. A.; Aveyard, P.; Ambrosini, G. L.; Perez-Cornago, A.; Carter, J.; Sun, X.; Piernas, C. Associations between dietary patterns and the incidence of total and fatal cardiovascular disease and all-cause mortality in 116,806 individuals from the UK Biobank: a prospective cohort study. BMC Med. 2021, 19 (1), 83. [CrossRef]
- AlFaris, N. A.; Alshammari, G. M.; AlTamimi, J. Z.; AlMousa, L. A.; AlKehayez, N. M.; Aljabryn, D. H.; Alagal, R. I.; Yahya, M. A. The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats. Saudi J. Biol. Sci. 2021, 28 (1), 170–182. [CrossRef]
- Tirosh, O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxid. Med. Cell. Longev. 2018, 2018, 1–15. [CrossRef]
- Cunha, L. F.; Ongaratto, M. A.; Endres, M.; Barschak, A. G. Modelling hypercholesterolaemia in rats using high cholesterol diet. Int. J. Exp. Pathol. 2021, 102 (2), 74–79. [CrossRef]
- Saigo, Y.; Sasase, T.; Tohma, M.; Uno, K.; Shinozaki, Y.; Maekawa, T.; Sano, R.; Miyajima, K.; Ohta, T. High-Cholesterol Diet in Combination With Hydroxypropyl-β Cyclodextrin Induces NASH-Like Disorders in the Liver of Rats. Physiol. Res. 2023, 72 (3). [CrossRef]
- Jang, S.; Lee, M.-S.; Kang, S.-A.; Kim, C.-T.; Kim, Y. Portulaca oleracea L. Extract Regulates Hepatic Cholesterol Metabolism via the AMPK/MicroRNA-33/34a Pathway in Rats Fed a High-Cholesterol Diet. Nutrients 2022, 14 (16), 3330. [CrossRef]
- Liu, L.; Zhang, M.; Jiang, F.; Luo, D.; Liu, S.; Su, Y.; Guan, Q.; Yu, C. High cholesterol diet–induced testicular dysfunction in rats. Hormones 2023, 22 (4), 685–694. [CrossRef]
- Yu, C.; Jiang, F.; Zhang, M.; Luo, D.; Shao, S.; Zhao, J.; Gao, L.; Zuo, C.; Guan, Q. HC diet inhibited testosterone synthesis by activating endoplasmic reticulum stress in testicular Leydig cells. J. Cell. Mol. Med. 2019, 23 (5), 3140–3150. [CrossRef]
- Zafar, H.; Ain, N. ul; Alshammari, A.; Alghamdi, S.; Raja, H.; Ali, A.; Siddique, A.; Tahir, S. D.; Akbar, S.; Arif, M.; Alharbi, M.; Rahman, A. Lacticaseibacillus rhamnosus FM9 and Limosilactobacillus fermentum Y57 Are as Effective as Statins at Improving Blood Lipid Profile in High Cholesterol, High-Fat Diet Model in Male Wistar Rats. Nutrients 2022, 14 (8), 1654. [CrossRef]
- Biryulina, N.A.; Sidorova, Yu.S.; Petrov, N.A.; Guseva, G.V.; Mazo, V.K. The effect of semi-synthetic and high-fat high-carbohydrate diets containing cholesterol on lipid and cholesterol metabolism of male Wistar rats. Bulletin of Experimental Biology and Medicine 2023, 175(4), 451–456. [CrossRef]
- Kovacs, P.; Hajnal, A. Short-term high-fat diet consumption increases body weight and body adiposity and alters brain stem taste information processing in rats. Chem Senses 2022 47, bjac020. [CrossRef]
- Moreno-Fernández, S.; Garcés-Rimón, M.; Vera, G.; Astier, J.; Landrier, J.F.; Miguel, M.; High Fat/High Glucose Diet Induces Metabolic Syndrome in an Experimental Rat Model. Nutrients 2018 10 (10), 1502. [CrossRef]
- Pathak, R.; Kumar, A.; Palfrey, H. A.; Stone, K. P.; Raju, N. R.; Gettys, T. W.; Murthy, S. N. Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague–Dawley rats fed a high-cholesterol diet. Inflamm. Res. 2022, 71 (5–6), 711–722. [CrossRef]
- Oda, E. A decrease in total bilirubin predicted hyper-LDL cholesterolemia in a health screening population. Atherosclerosis 2014, 235 (2), 334–338. [CrossRef]
- Su, Q.; Chen, H.; Du, S.; Dai, Y.; Chen, C.; He (何天敏), T.; Feng, R.; Tao, T.; Hu, Z.; Zhao, H.; Guo, P.; Ye, W. Association Between Serum Bilirubin, Lipid Levels, and Prevalence of Femoral and Carotid Atherosclerosis: A Population-Based Cross-Sectional Study. Arterioscler. Thromb. Vasc. Biol. 2023, 43 (1), 136–145. [CrossRef]
- Li, X.-H.; Lin, H.-Y.; Guan, L.-Y.; Peng, H.; Wen, M.-M.; Cao, Y.-Q.; Jiang, X.-Y.; Wang, Y.-B. Direct Bilirubin Levels and Risk of Metabolic Syndrome in Healthy Chinese Men. Biomed Res. Int. 2017, 2017, 1–8. [CrossRef]
- Wu, I.-T.; Yeh, W.-J.; Huang, W.-C.; Yang, H.-Y. Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem. 2024, 126, 109583. [CrossRef]
- Spassiani, N. A.; Kuk, J. L. Exercise and the fatty liver. Appl. Physiol. Nutr. Metab. 2008, 33 (4), 802–807. [CrossRef]
- Botezelli, J. D.; Mora, R. F.; Dalia, R. A.; Moura, L. P.; Cambri, L. T.; Ghezzi, A. C.; Voltarelli, F. A.; Mello, M. A. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis. 2010, 9 (1), 116. [CrossRef]
- Gu, X.; Ma, X.; Mo, L.; Wang, Q. The Role of Exercise Intensity on Fatty Liver in Rats. Chin. J. Physiol. 2022, 65 (6), 301–310. [CrossRef]
- Pan, M.; Song, Y.; Xu, J.; Gan, H. Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. J. Pineal Res. 2006, 41 (1), 79–84. [CrossRef]
- Qi, J.; Kim, J.-W.; Zhou, Z.; Lim, C.-W.; Kim, B. Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation–Mediated Cell Death in Mice. Am. J. Pathol. 2020, 190 (1), 68–81. [CrossRef]
- Münzberg, H.; Morrison, C. D. Structure, production and signaling of leptin. Metabolism 2015, 64 (1), 13–23. [CrossRef]
- Martelli, D.; Brooks, V. L. Leptin Increases: Physiological Roles in the Control of Sympathetic Nerve Activity, Energy Balance, and the Hypothalamic–Pituitary–Thyroid Axis. Int. J. Mol. Sci. 2023, 24 (3), 2684. [CrossRef]
- Ferreira-Halder, C. V.; Faria, A. V. de S.; Andrade, S. S. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract. Res. Clin. Gastroenterol. 2017, 31 (6), 643–648. [CrossRef]
- Leylabadlo, H. E.; Ghotaslou, R.; Feizabadi, M. M.; Farajnia, S.; Moaddab, S. Y.; Ganbarov, K.; Khodadadi, E.; Tanomand, A.; Sheykhsaran, E.; Yousefi, B.; Kafil, H. S. The critical role of Faecalibacterium prausnitzii in human health: An overview. Microb. Pathog. 2020, 149, 104344. [CrossRef]
- Sitkin, S. I.; Vakhitov, T. Y.; Tkachenko, E. I.; Oreshko, L. S.; Zhigalova, T. N.; Radchenko, V. G.; Seliverstov, P. V.; Avalueva, E. B.; Suvorova, M. A.; Komlichenko, E. V. Gut microbiota in ulcerative colitis and celiac disease. Exp. Clin. Gastroenterol. 2017, No 1, 8–30.
- Mohammad, S.; Thiemermann, C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Front. Immunol. 2021, 11. [CrossRef]
- Khare, A.; Gaur, S. Cholesterol-Lowering Effects of Lactobacillus Species. Curr. Microbiol. 2020, 77 (4), 638–644. [CrossRef]
- O’Flaherty, S.; Briner Crawley, A.; Theriot, C. M.; Barrangou, R. The Lactobacillus Bile Salt Hydrolase Repertoire Reveals Niche-Specific Adaptation. mSphere 2018, 3 (3). [CrossRef]
- Frappier, M.; Auclair, J.; Bouasker, S.; Gunaratnam, S.; Diarra, C.; Millette, M. Screening and Characterization of Some Lactobacillaceae for Detection of Cholesterol-Lowering Activities. Probiotics Antimicrob. Proteins 2022, 14 (5), 873–883. [CrossRef]
- de Araújo Henriques Ferreira, G.; Magnani, M.; Cabral, L.; Brandão, L. R.; Noronha, M. F.; de Campos Cruz, J.; de Souza, E. L.; de Brito Alves, J. L. Potentially Probiotic Limosilactobacillus fermentum Fruit-Derived Strains Alleviate Cardiometabolic Disorders and Gut Microbiota Impairment in Male Rats Fed a High-Fat Diet. Probiotics Antimicrob. Proteins 2022, 14 (2), 349–359. [CrossRef]
- Li, X.; Xiao, Y.; Huang, Y.; Song, L.; Li, M.; Ren, Z. Lactobacillus gasseri RW2014 Ameliorates Hyperlipidemia by Modulating Bile Acid Metabolism and Gut Microbiota Composition in Rats. Nutrients 2022, 14 (23), 4945. [CrossRef]
- Kumar, M.; Nagpal, R.; Kumar, R.; Hemalatha, R.; Verma, V.; Kumar, A.; Chakraborty, C.; Singh, B.; Marotta, F.; Jain, S.; Yadav, H. Cholesterol-Lowering Probiotics as Potential Biotherapeutics for Metabolic Diseases. Exp. Diabetes Res. 2012, 2012, 1–14. [CrossRef]
- DiRienzo, D. B. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutr. Rev. 2014, 72 (1), 18–29. [CrossRef]
- Tonucci, L. B.; Olbrich dos Santos, K. M.; Licursi de Oliveira, L.; Rocha Ribeiro, S. M.; Duarte Martino, H. S. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin. Nutr. 2017, 36 (1), 85–92. [CrossRef]
- Choi, B. S.-Y.; Brunelle, L.; Pilon, G.; Cautela, B. G.; Tompkins, T. A.; Drapeau, V.; Marette, A.; Tremblay, A. Lacticaseibacillus rhamnosus HA-114 improves eating behaviors and mood-related factors in adults with overweight during weight loss: a randomized controlled trial. Nutr. Neurosci. 2023, 26 (7), 667–679. [CrossRef]
- Huang, W.; Wang, G.; Xia, Y.; Xiong, Z.; Ai, L. Bile salt hydrolase-overexpressing Lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model. Food Nutr. Res. 2020, 64. [CrossRef]
- Reeves, P. G. Components of the AIN-93 Diets as Improvements in the AIN-76A Diet. J. Nutr. 1997, 127 (5), 838S-841S. [CrossRef]
- Omar, A. M.; Zhang, Q. Evaluation of Lipid Extraction Protocols for Untargeted Analysis of Mouse Tissue Lipidome. Metabolites 2023, 13 (9), 1002. [CrossRef]





| Parameter | Animal group | ||||
| Control | 1% Chol | 2% Chol | 1% Chol + RUN | 2% Chol + RUN | |
| Test 1 (before the start of the experiment) | |||||
| Fat content, % | 9.2±0.5 | 8.3±0.5 | 10.0±1.2 | 8.2±0.7 | 9.8±0.7 |
| Lean weight, % | 85.5±0.5 | 86.4±0.9 | 84.8±1.2 | 86.8±0.7 | 84.7±0.6 |
| Free water, % | 0.25±0.03 | 0.26±0.02 | 0.32±0.05 | 0.22±0.01 | 0.22±0.02 |
| Total water, % | 74.1±0.5 | 74.7±0.8 | 73.4±1.0 | 74.9±0.7 | 73.9±0.6 |
| Test 2 (33rd day) | |||||
| Fat content, % | 9.5±1.1 | 5.3±0.81* | 10.4±2.02 | 5.1±1.01,3* | 6,5±1,3* |
| Lean weight, % | 85.6±1.1 | 90.2±0.81* | 85.0±2.12 | 90.6±1.01,3* | 88.6±1.2* |
| Free water, % | 0.24±0.02 | 0.27±0.03 | 0.30±0.031 | 0.29±0.021 | 0.30±0.021 |
| Total water, % | 72.3±1.0 | 76.1±0.61 | 70.7±1.72 | 76.5±0.91,3 | 75.0±1.1 |
| Test 3 (66th day) | |||||
| Fat content, % | 10.3±1.2 | 5.4±0.71* | 12.7±2.62 | 5.5±1.21,3* | 6.3±1.41,3* |
| Lean weight, % | 83.5±1.2 | 88.9±0.71* | 81.3±2.72 | 89.1±1.11,3 | 88.0±1.41,3* |
| Free water, % | 0.18±0.01 | 0.26±0.05 | 0.20±0.02 | 0.24±0.05 | 0.19±0.03 |
| Total water, % | 70.2±0.9* | 74.7±0.61 | 68.4±2.22 | 75.1±1.01,3 | 74.1±1.21,3 |
| Test 4 (82nd day) | |||||
| Fat content, % | 10.5±1.0 | 5.4±0.71,3* | 15.4±2.21 | 5.8±1.31,3 | 6.7±1.51,3* |
| Lean weight, % | 83.2±1.0* | 88.6±0.71,3 | 78.2±2.31 | 88.2±1.21,3 | 87.1±1.61,3 |
| Free water, % | 0.27±0.02 | 0.31±0.03 | 0.27±0.03 | 0.24±0.02 | 0.24±0.03 |
| Total water, % | 69.2±1.0* | 74.5±0.61,3 | 67.1±2.21* | 74.5±1.11,3 | 73.3±1.31,3 |
| Parameter | Animal groups | ||||
| Control | 1% Chol | 2% Chol | 1% Chol + RUN | 2% Chol + RUN | |
| Leukocytes, 109/l | 5.5 (4.6-6.4) | 6.5 (5.4-7.4) |
4.3 (3.8-5.5)2 |
7.8 (5.2-9.2)3 | 5.9 (4.9-6.7)3 |
| Lymphocytes, 109/l | 3.6 (3.1-4.5) | 4.0 (3.3-4.9) |
2.8 (1.9-3.5)2 |
4.8 (3.3-6.6)3 | 4.0 (2.9-4.4) |
| Lymphocytes, % | 66.2±2.1 | 64.1±2.8 | 61.5±3.3 | 66.1±2.3 | 61.6±2.1 |
| Monocytes, 109/l | 0.24±0.03 | 0.36±0.05 | 0.20±0.052 | 0.26±0.03 | 0.31±0.05 |
| Monocytes, % | 4.3 (3.8-7.3) | 7.2 (5.1-7.7) | 4.5 (4.0-7.6) |
3.8 (3.3-4.9) | 7.3 (3.7-8.1) |
| Granulocytes, 109/l | 1.6 (1.2-1.8) | 2.1 (1.3-2.3) |
1.1 (0.9-1.5)2 |
2.0 (1.7-2.3)3 | 1.7 (1.5-2.0) |
| Granulocytes, % | 29.7 (23.6-34.7) | 28.9 (27.3-34.5) | 28.4 (22.4-43.4) | 29.9 (24.5-33.8) | 30.6 (28.5-35.6) |
| Hemoglobin, g/l | 153 (151-157) | 146 (146-150) | 150 (147-152) | 150 (144-155) | 155 (154-156)2 |
| Average hemoglobin content in an erythrocyte, pg | 18.7±0.2 | 18.4±0.3 | 17.9±0.21 | 18.6±0.13 | 18.7±0.23 |
| Average concentration of cellular hemoglobin in erythrocytes, g/l | 365.7±2.4 | 374.8±1.6 | 371.2±1.5 | 370.1±1.4 | 367.4±1.0 |
| Erythrocytes, 1012/л | 8.3 (8.0-8.5) | 8.1 (7.9-8.2) | 8.4 (8.2-8.5) |
7.9 (7.8-8.3) | 8.3 (8.2-8.3) |
| Average erythrocyte volume, fl | 50.6 (50.0-51.9) | 48.9 (47.4-50.9) | 48.0 (47.4-48.7)1,2 | 50.6 (49.6-51.1)3 | 51.2 (50.0-51.7)2,3 |
| Hematocrit, % | 42.2±0.6 | 39.7±0.71 | 40.3±0.31 | 40.3±0.61 | 42.1±0.52,3,4 |
| Width of distribution of red blood cells by volume, % | 13.0 (12.8-13.5) | 13.2 (13.1-13.7) | 13.7 (13.2-14.0) | 13.3 (13.1-13.5) | 13.1 (12.7-13.6) |
| Width of distribution of red blood cells by volume, fl | 31.2±0.4 | 29.9±0.4 | 29.9±0.4 | 30.7±0.2 | 31.3±0.4 |
| Platelets, 109/l | 705.3±71.2 | 738.7±73.8 | 726.0±63.5 | 761.6±54.9 | 705.6±45.7 |
| Platelets average volume, fl | 6.39±0.14 | 6.20±0.10 | 6.10±0.10 | 6.21±0.09 | 6.33±0.07 |
| Parameter | Animal groups | ||||
| Control | 1% Chol | 2% Chol | 1% Chol + RUN | 2% Chol + RUN | |
| Total protein, g/l | 75,0 (69,7-77,8) | 77,3 (74,2-82,6) | 82,1 (78,2-88,7)1 | 76,4 (73,8-82,1) | 81,9 (77,4-83,9)1 |
| Albumin, g/l | 35,8 (35,5-36,0) | 35,5 (35,1-36,8) | 37,2 (35,9-38,1) | 36,1 (35,6-36,9) | 36,7 (36,0-37,4) |
| Globulins, g/l | 38,2±1,5 | 42,6±1,6 | 45,7±2,51 | 41,7±1,8 | 44,6±1,51 |
| Cholesterol, mmol/l | 1,5 (1,4-1,6) | 1,8 (1,3-1,9) | 2,8 (2,2-2,9)1,2 | 1,8 (1,7-1,9)3 | 2,2 (1,8-2,8)1,2 |
| Triglycerides, mmol/l | 1,0 (0,8-2,3) | 0,8 (0,7-1,1) | 0,9 (0,7-1,6) | 0,8 (0,6-0,9) | 1,0 (0,6-1,1) |
| HDL, mmol/l | 1,2 (1,1-1,4) | 0,9 (0,8-1,0)1 | 1,1 (1,1-1,2)2 | 0,9 (0,8-0,9)1,3 | 1,1 (1,0-1,2)2,4 |
| LDL, mmol/l | 0,07 (0,05-0,08) | 0,13 (0,09-0,27)1 | 0,20 (0,11-0,24)1 | 0,12 (0,10-0,14)1 | 0,12 (0,08-0,21)1 |
| Atherogenic coefficient | 0,23 (0,14-0,27) | 0,85 (0,49-1,15)1 | 1,20 (0,99-1,63)1 | 1,03 (0,89-1,13)1 | 1,07 (0,45-1,88)1 |
| Total bilirubin, μmol/l | 4,27±0,22 | 3,77±0,141 | 3,48±0,111 | 3,57±0,071 | 3,24±0,221,2 |
| Creatinine, μmol/l | 53,1 (51,3-56,1) | 52,4 (51,7-53,1) | 57,5 (53,1-59,0)2 | 53,3 (53,0-56,1) | 57,0 (55,3-58,6)1,2 |
| Alkaline phosphatase, U/l | 101 (88-121) | 115 (98-124) | 123 (112-155) | 117 (97-147) | 162 (129-183)1 |
| ALT, U/l | 56,6 (55,4-65,4) | 56,4 (49,0-64,3) | 80,7 (75,3-109,5)1,2 | 59,7 (50,2-65,5)3 | 91,7 (72,2-157,0)1,2,4 |
| AST, U/l | 39,4±3,9 | 53,5±5,1 | 60,1±4,61 | 60,0±7,21 | 42,3±4,93 |
| AST/ALT | 0,70±0,10 | 0,92±0,14 | 0,67±0,10 | 0,98±0,09 | 0,45±0,112,4 |
| Urea, mmol/l | 5,0±0,2 | 4,7±0,1 | 5,1±0,3 | 4,8±0,2 | 5,0±0,1 |
| Uric acid, μmol/l | 86,6±3,4 | 91,1±4,6 | 88,2±5,5 | 83,1±2,6 | 87,1±3,4 |
| Phosphor, mmol/l | 2,27±0,04 | 2,37±0,06 | 2,28±0,05 | 2,39±0,09 | 2,45±0,07 |
| Magnesium, mmol/l | 0,89 (0,87-0,96) | 0,83 (0,76-0,86) | 0,91 (0,86-0,96) | 0,91 (0,83-0,99) | 0,90 (0,90-0,92)2 |
| Calcium, mmol/l | 2,95 (2,94-3,00) | 3,01 (2,97-3,03) | 3,05 (2,99-3,08)1 | 3,02 (2,97-3,08) | 3,16 (3,06-3,21)1,2,4 |
| Glucose, mmol/l | 5,7±0,3 | 5,7±0,1 | 6,2±0,3 | 5,7±0,2 | 6,3±0,2 |
| Parameter | Animal groups | ||||
| Control | 1% Chol | 2% Chol | 1% Chol + RUN | 2% Chol + RUN | |
| Liver weight, g | 11.4 (10.0-11.7) | 14.3 (13.9-17.2)1 | 14.2 (13.8-17.7)1 | 15.1 (13.8-16.6)1 | 14.5 (14.0-18.4)1 |
| Relative liver weight, % | 2.3 (2.2-2.4) | 3.0 (2.6-3.2)1 | 3.2 (2.9-3.4)1 | 2.9 (2.9-3.1)1 | 3.0 (2.9-3.7)1 |
| Fat, mg/g of liver | 66.4 (63.6-70.2) | 138.7 (118.2-163.5)1 | 154.5 (128.3-223.2)1 | 150.4 (129.0-159.5)1 | 158.2 (108.9-210.4)1 |
| Triglycerides, mg/g | 6.6 (4.4-13.4) | 31.2 (16.3-37.3)1 | 31.4 (23.2-36.2)1 | 18.8 (6.6-30.9) | 20.4 (9.8-30.2)1 |
| Cholesterol, mg/g | 3.0 (2.5-3.4) | 20.6 (16.4-22.4)1 | 23.6 (17.5-28.2)1 | 18.6 (15.6-22.8)1 | 17.5 (11.9-22.1)1 |
| Populations and groups of microorganisms | Control | 1% Chol | 2% Chol | 1% Chol + RUN | 2% Chol + RUN | |||||
| Me (Q1-Q3) | % detected | Me (Q1-Q3) | % detected | Me (Q1-Q3) | % detected | Me (Q1-Q3) | % detected | Me (Q1-Q3) | % detected | |
| Total bacterial mass | 12.9 [12.8 – 13.0] |
100 | 13.0 [13.0 – 13.2] |
100 | 12.8 [12.8 – 13.0] |
83 | 12.9 [12.8 – 13.0] |
100 | 12.9 [12.7 – 13.0] |
100 |
| Lactobacillus spp. | 7.8 [7.6 – 8.5] |
100 | 8.7 [8.4 – 9.3] |
100 |
9.0 1 [8.8 – 9.4] |
100 |
9.2 1 [8.8 – 9.4] |
100 |
9.0 1 [8.8 – 9.2] |
100 |
| Bifidobacterium spp. | 10.5 [8.9 – 11.5] |
100 | 8.7 [8.5 – 8.8] |
100 | 8.5 [8.1 – 8.8] |
100 |
8.3 1 [8.3 – 8.7] |
100 |
8.3 1 [8.1 – 8.4] |
100 |
| Escherichia coli | 6,8 [6,6,7,6] |
100 |
8.5 1 [8.2 – 8.9] |
100 |
8.2 1 [8.0 – 8.3] |
100 |
8.5 1 [7.3 – 8.7] |
100 | 8.0 [7.9 – 8.2] |
100 |
| Bacteroides spp. | 11.7 [11.4 – 11.9] |
100 | 12.3 [12.0 – 12.3] |
100 | 11.9 [11.6 – 11.9] |
100 | 11.8 [11.7 – 12.0] |
100 | 11.8 [11.6 – 12.0] |
100 |
| Faecalibacterium prausnitzii | 9.0 [8.8 – 9.2] |
100 |
8.0 1 [8.0 – 8.2] |
100 |
8.2 1 [7.9 – 8.5] |
100 |
8.7 2 [8.4 – 8.8] |
100 |
8.2 1 [7.8 – 8.5] |
100 |
| Enterococcus spp. | 5.7 [5.6 – 5.7] |
33 | 7.3 [7.3 – 7.3] |
17 | – | 0 | 7.2 [6.0 – 8.5] |
33 | – | 0 |
| Staphylococcus aureus | – | 0 | 7.5 [6.7 – 8.2] |
75 | 6.5 [6.5 – 6.5] |
33 | – | 0 | 6.5 [6.5 – 6.5] |
33 |
| Proteus vulgaris/mirabilis | – | 0 | – | 0 | – | 0 | 5.8 [5.8 – 5.8] |
33 | – | 0 |
| Blautia spp. | 10.4 [10.3 – 10.8] |
100 |
11.5 1 [11.4 – 11.8] |
100 | 11.5 [11.1 – 11.5] |
100 | 11.3 [11.1 – 11.4] |
100 | 11.1 [10.9 – 11.5] |
100 |
| Acinetobacter spp. | 8.5 [8.3 – 8.6] |
100 | 8.6 [8.5 – 8.8] |
100 |
8.2 1,2 [8.0 – 8.3] |
100 |
8.3 2 [8.1 – 8.3] |
100 |
8.0 1,2 [8.0 – 8.0] |
100 |
| Streptococcus spp. | 7.5 [7.2 – 7.8] |
67 | 7.7 [7.7 – 7.8] |
100 | 7.6 [7.3 – 7.7] |
100 | 7.3 [7.1 – 7.7] |
100 |
7.4 2 [7.3 – 7.6] |
100 |
| Roseburia inulinivorans | 8.5 [8.5 – 8.7] |
100 | 8.7 [8.6 – 8.8] |
100 | 8.7 [8.5 – 8.8] |
100 | 8.6 [8.5 – 8.8] |
100 | 8.7 [8.6 – 8.9] |
100 |
| Prevotella spp. | 8.0 [7.1 – 8.5] |
67 | 7.5 [7.2 – 7.7] |
50 | 6.8 [6.6 – 6.9] |
100 | 6.3 [5.7 – 7.8] |
83 | 6.7 [6.4 – 6.9] |
100 |
| Ruminococcus spp. | 7.7 [7.7 – 7.7] |
17 |
9.8 1 [9.4 – 11.5] |
83 | 8.7 [8.6 – 8.7] |
33 | 10.5 [10.2 – 10.9] |
33 | 8.5 [8.2 – 10.2] |
50 |
| Bacteroides spp. and F. prausnitzii (Bfr/Fprau) ratio | 338 [133,3 – 1361,1] |
– |
12571 1 [4285 – 20000] |
– |
5476 1 [2821 – 8416] |
– |
2500 2 [1160 – 3125] |
– |
4166 1 [1833 – 8750] |
– |
| Parameter | Animal group | ||||
| Control | 1% Chol | 2% Chol | 1% Chol + RUN | 2% Chol + RUN | |
| Body weight, g | 302,2±4,0 | 302,2±6,4 | 302,0±6,5 | 302,9±5,7 | 302,1±3,5 |
| Time in center, sec | 5,9±1,8 | 5,7±1,8 | 6,1±2,2 | 7,2±2,2 | 5,6±1,4 |
| Zone transitions | 10,7±1,9 | 12,9±1,6 | 12,6±2,3 | 12,6±2,0 | 11,6±1,7 |
| Distance, sec | 1764±92 | 1762±112 | 1783±105 | 1720±94 | 1692±135 |
| Days of experiment | Speed, cm/sec | Time, min | Track slope, degrees |
| 9 11 16 18 | 20 | 10 | 0 |
| 23 25 30 32 | 24 | 10 | 0 |
| 37 39 44 46 51 53 | 26 | 10 | 0 |
| 58 60 65 67 71 74 79 | 28 | 10 | 0 |
| 81 85 88 92 93 | 30 | 10 | 0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).